Insider and congress filings
Vertex Pharmaceuticals Incorporated (VRTX)
About Vertex Pharmaceuticals Incorporated
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Reshma Kewalramani
- Employees
- 6,400
- Listed since
- Jul 24, 1991
- Market value
- $132.3B
- Price to earnings
- 30.1
- Earnings per share
- $17.35
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 2, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | $4.73 | $4.74 | $3.3B | $3.2B | EPS in lineRevenue beat |
| Q1 FY2026reported May 4, 2026 | $4.47 | $4.24 | $3.0B | $3.0B | EPS beatRevenue in line |
| Q4 FY2025reported Feb 12, 2026 | $5.03 | $5.11 | $3.2B | $3.2B | EPS missRevenue in line |
| Q3 FY2025reported Nov 3, 2025 | $4.80 | $4.57 | $3.1B | $3.1B | EPS beatRevenue in line |
| Q2 FY2025reported Aug 4, 2025 | $4.52 | $4.29 | $3.0B | $2.9B | EPS beatRevenue beat |
| Q1 FY2025reported May 5, 2025 | $4.06 | $4.25 | $2.8B | $2.9B | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 2, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Reshma KewalramaniCEO and President | $1.6M | $15.0M | $4.5M | $21.1M |
| Charles F. Wagner, Jr.EVP & Chief Operating and Financial Officer | $975K | $5.3M | $2.0M | $8.2M |
| Nia TatsisEVP & Chief Regulatory and Quality Officer | $750K | $4.9M | $1.3M | $7.0M |
| Amit SachdevEVP & Chief Patient and External Affairs Officer | $700K | $4.9M | $1.2M | $6.8M |
| Carmen BozicEVP & Chief Medical Officer | $835K | $4.4M | $1.4M | $6.6M |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Capital World Investors | $13.0B | 26,115,014 | +2.9% | 10.29% |
| Blackrock, Inc. | $12.0B | 24,109,373 | +0.6% | 9.50% |
| Capital Research Global Investors | $9.7B | 19,490,637 | -7.7% | 7.68% |
| Vanguard Capital Management LLC | $8.2B | 16,580,713 | +0.4% | 6.53% |
| State Street Corp | $5.9B | 11,871,459 | +1.2% | 4.68% |
| Invesco Ltd. | $4.0B | 8,043,052 | +50.9% | 3.17% |
| Jpmorgan Chase & Co | $3.3B | 6,517,600 | -7.3% | 2.57% |
| Geode Capital Management, LLC | $3.0B | 6,017,848 | -2.0% | 2.37% |
| Vanguard Portfolio Management LLC | $2.4B | 4,878,987 | -5.2% | 1.92% |
| Capital International Investors | $2.3B | 4,695,144 | -8.4% | 1.85% |
| Loomis Sayles & Co L P | $1.9B | 3,920,953 | -2.1% | 1.54% |
| Franklin Resources Inc | $1.7B | 3,347,253 | +507.3% | 1.32% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
20 filings of 382 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Duncan McKechnieEVP, Chief Commercial Officer | Sold | 1,541 | $519.00 | $800K | Jul 2, 2026 | 5d |
| Ourania TatsisEVP, Chief Reg. & Quality Off. | Sold | 1,500 | $524.99 | $787K | Jul 2, 2026 | 5d |
| Joy LiuEVP and Chief Legal Officer | Sold | 828 | $502.71 | $416K | Jul 1, 2026 | 5d |
| Carmen BozicEVP and CMO | Sold | 596 | $482.50 | $288K | Jun 26, 2026 | 4d |
| Carmen BozicEVP and CMO | Sold | 1,020 | $462.17 | $471K | Jun 18, 2026 | 5d |
| Carmen BozicEVP and CMO | Sold | 4,062 | $450.00 | $1.8M | Jun 15, 2026 | 2d |
| Carmen BozicEVP and CMO | Sold | 1,745 | $450.00 | $785K | Jun 5, 2026 | 4d |
| Carmen BozicEVP and CMO | Sold | 1,974 | $450.00 | $888K | May 29, 2026 | 4d |
| Mark E. BunnageEVP, Chief Scientific Officer | Sold | 33 | $453.45 | $15K | May 15, 2026 | 4d |
| Carmen BozicEVP and CMO | Sold | 1,354 | $453.45 | $614K | May 15, 2026 | 4d |
| Carmen BozicEVP and CMO | Sold | 6,988 | $450.00 | $3.1M | May 12, 2026 | 2d |
| Joy LiuEVP and Chief Legal Officer | Sold | 1,104 | $425.02 | $469K | May 1, 2026 | 4d |
| Sangeeta N. BhatiaDirector | Sold | 318 | $423.73 | $135K | May 4, 2026 | 1d |
| Joy LiuEVP and Chief Legal Officer | Sold | 978 | $449.17 | $439K | Apr 1, 2026 | 2d |
| Carmen BozicEVP and CMO | Sold | 2,329 | $450.95 | $1.1M | Mar 27, 2026 | 4d |
| Carmen BozicEVP and CMO | Sold | 2,329 | $481.79 | $1.1M | Mar 13, 2026 | 4d |
| Duncan McKechnieEVP, Chief Commercial Officer | Sold | 2,633 | $498.42 | $1.3M | Mar 11, 2026 | 2d |
| Duncan McKechnieEVP, Chief Commercial Officer | Sold | 2,437 | $475.30 | $1.2M | Mar 4, 2026 | 2d |
| Joy LiuEVP and Chief Legal Officer | Sold | 892 | $495.96 | $442K | Mar 2, 2026 | 2d |
| Reshma KewalramaniCEO & President | Sold · 13 lines | 40,000 | $493.47 | $19.7M | Feb 27, 2026 | 4d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in VRTX
20 disclosures of 48 on record · median 35d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| David Taylor | Stock | Sale | $1,001 - $15,000 | -4.8%S&P -0.5% · vs S&P 500 -4.3% | Aug 26, 2026 | Sep 5, 2026 | 10d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +20.3%S&P +20.2% · vs S&P 500 +0.1% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| David Taylor | Stock | Sale | $1,001 - $15,000 | +9.6%S&P +9.8% · vs S&P 500 -0.3% | Jan 29, 2026 | Feb 2, 2026 | 4d |
| Julia LetlowFiled late | Stock | Purchase | $1,001 - $15,000 | +10.9%S&P +32.1% · vs S&P 500 -21.3% | Oct 23, 2024 | Jan 13, 2026 | 447d |
| David Taylor | Stock | Purchase | $1,001 - $15,000 | +38.7%S&P +20.6% · vs S&P 500 +18.2% | Aug 7, 2025 | Sep 2, 2025 | 26d |
| Lisa C. McClainSpouseFiled late | Stock | Purchase | $1,001 - $15,000 | +11.3%S&P +25.7% · vs S&P 500 -14.4% | Dec 11, 2024 | Aug 13, 2025 | 245d |
| Lisa C. McClainSpouseFiled late | Stock | Sale | $1,001 - $15,000 | +15.2%S&P +27.0% · vs S&P 500 -11.8% | Jun 11, 2025 | Aug 13, 2025 | 63d |
| Lisa C. McClainSpouseFiled late | Stock | Sale | $1,001 - $15,000 | +15.4%S&P +26.6% · vs S&P 500 -11.2% | Jun 10, 2025 | Aug 13, 2025 | 64d |
| Jefferson Shreve | Stock | Sale | $15,001 - $50,000 | +18.6%S&P +30.8% · vs S&P 500 -12.2% | May 12, 2025 | Jun 22, 2025 | 41d |
| Byron Donalds | Stock | Sale | $1,001 - $15,000 | +2.1%S&P +34.8% · vs S&P 500 -32.6% | Mar 20, 2025 | Apr 14, 2025 | 25d |
| Jefferson Shreve | Stock | Purchase | $15,001 - $50,000 | +3.6%S&P +38.2% · vs S&P 500 -34.6% | Mar 13, 2025 | Apr 11, 2025 | 29d |
| Jefferson Shreve | Stock | Purchase | $15,001 - $50,000 | +8.2%S&P +27.6% · vs S&P 500 -19.4% | Feb 24, 2025 | Mar 9, 2025 | 13d |
| Tommy TubervilleJoint | Stock | Sale (Full) | $1,001 - $15,000 | +29.9%S&P +49.1% · vs S&P 500 -19.2% | May 3, 2024 | Jun 14, 2024 | 42d |
| Greg StantonSpouse | Stock | Sale | $1,001 - $15,000 | +41.1%S&P +80.4% · vs S&P 500 -39.3% | Oct 24, 2023 | Nov 9, 2023 | 16d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +49.7%S&P +74.1% · vs S&P 500 -24.5% | Jun 29, 2023 | Jul 11, 2023 | 12d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +69.6%S&P +94.5% · vs S&P 500 -24.9% | Dec 6, 2022 | Jan 6, 2023 | 31d |
| Tommy TubervilleJoint | Stock | Purchase | $1,001 - $15,000 | +74.5%S&P +104.4% · vs S&P 500 -29.9% | Oct 6, 2022 | Nov 10, 2022 | 35d |
| William R. Keating | Stock | Purchase | $1,001 - $15,000 | +102.0%S&P +65.2% · vs S&P 500 +36.8% | Mar 29, 2022 | May 5, 2022 | 37d |
| Diana HarshbargerFiled late | Stock | Sale | $1,001 - $15,000 | +178.2%S&P +63.2% · vs S&P 500 +115.1% | Nov 12, 2021 | Dec 30, 2021 | 48d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +98.6%S&P +169.0% · vs S&P 500 -70.4% | Apr 14, 2020 | May 13, 2020 | 29d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
5 members · estimate, as of Sep 10, 20265 members report a position (estimated). The largest estimated position is in the $15,001 - $50,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Democrat · House | $15,001 - $50,000 | 0.1% |
| Robert Bresnahan | Republican · House | $15,001 - $50,000 | 0.3% |
| Harriet M. Hageman | Republican · House | $1,001 - $15,000 | 0.3% |
| Julie Johnson | Democrat · House | $1,001 - $15,000 | 0.1% |
| William R. Keating | Democrat · House | $1,001 - $15,000 | 1.1% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Kristen AmbroseSVP & Chief Accounting Officer | Stock award | 5,000 | Aug 28, 2026 |
| Bruce I. SachsDirector | Gift | 6,000 | Aug 27, 2026 |
| Amit SachdevEVP Chief Patient & Ext Af Off | Stock award | 8,251 | Jul 21, 2026 |
| Ourania TatsisEVP, Chief Reg. & Quality Off. | Stock award | 8,251 | Jul 21, 2026 |
| Bruce I. SachsDirector | Stock award | 100 | Jul 15, 2026 |
| Alan M. GarberDirector | Stock award | 32 | Jul 15, 2026 |
| Jennifer SchneiderDirector | Disposed to issuer | 796 | May 1, 2026 |
| Suketu UpadhyayDirector | Stock award | 3,662 | May 1, 2026 |
| Jennifer SchneiderDirector | Stock award | 2,701 | May 1, 2026 |
| Suketu UpadhyayDirector | Disposed to issuer | 796 | May 1, 2026 |
| Nancy ThornberryDirector | Stock award | 2,303 | May 1, 2026 |
| Michel LagardeDirector | Stock award | 2,866 | May 1, 2026 |
| Nancy ThornberryDirector | Disposed to issuer | 398 | May 1, 2026 |
| Alan M. GarberDirector | Stock award | 1,905 | May 1, 2026 |
| Lloyd CarneyDirector | Stock award | 2,866 | May 1, 2026 |
| Sangeeta N. BhatiaDirector | Stock award | 943 | May 1, 2026 |
| Bruce I. SachsDirector | Stock award | 2,866 | May 1, 2026 |
| Diana MckenzieDirector | Stock award | 1,739 | May 1, 2026 |
| Diana MckenzieDirector | Disposed to issuer | 796 | May 1, 2026 |
| Alan M. GarberDirector | Stock award | 34 | Apr 15, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling VRTX?
Across the 20 most recent open-market filings shown here, 0 were purchases and 20 were sales.
Which members of Congress have traded VRTX?
David Taylor, Alan Armstrong, Julia Letlow, Lisa C. McClain, Jefferson Shreve, Byron Donalds and others disclosed VRTX transactions in the filings shown here.
Which members of Congress hold VRTX?
5 members of Congress report a position in VRTX in the estimate we hold as of Sep 10, 2026. The three largest estimated positions belong to Gilbert Ray Cisneros, Jr., Robert Bresnahan and Harriet M. Hageman. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is VRTX in the S&P 500 or the Nasdaq 100?
Vertex Pharmaceuticals Incorporated is a current member of the S&P 500 and Nasdaq 100, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are VRTX trades disclosed?
Insider filings on this page reached the public a median of 4 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 35 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.